Lupin Secures U.S. FDA Approval for Dapagliflozin Tablets

Lupin Limited announced April 7, 2026, that it has received approval from the U.S. Food and Drug Administration (FDA) for its Dapagliflozin Tablets in 5 mg and 10 mg strengths. These tablets, bioequivalent to Farxiga®, are indicated for specific uses in managing diabetes.

This U.S. FDA approval marks a significant step for Lupin's expansion in the anti-diabetic segment. The company reported consolidated revenue of INR 71,675.2 million and a net profit of INR 11,805.1 million for Q3 FY26, with EBITDA margins expanding to 31.1%.

Why This Matters

Gaining FDA approval for a generic version of Dapagliflozin is vital for Lupin to increase its market share in the competitive U.S. pharmaceutical market. This move strengthens Lupin's position in the anti-diabetic field, a major global drug segment, and opens opportunities for future revenue growth.

Lupin's U.S. Market Presence

Lupin has a consistent track record of obtaining U.S. FDA approvals and launching generics in the United States. Its U.S. business is a key revenue driver, with Q3 FY26 sales in the region reaching INR 3,113.2 crore, representing 44% of its global sales.

Competitive Landscape

The market for Dapagliflozin generics is highly competitive. Rivals such as Zydus Lifesciences and Alembic Pharmaceuticals have also secured U.S. FDA approvals for their versions of the drug. Alembic received final approval and eligibility for 180-day exclusivity. Sun Pharmaceutical Industries is another significant Indian competitor active in the U.S. generics and anti-diabetic markets.

Regulatory and Market Risks

Lupin has previously faced U.S. FDA scrutiny, including quality issue notices in 2019 and an 'Official Action Indicated' classification for its Pithampur Unit 2 facility in October 2025. Intense competition in the U.S. generics market, from both established and new players, can also lead to pricing pressures.

What's Next

Investors will be watching Lupin's launch strategy and timeline for the Dapagliflozin tablets in the U.S. Performance against competitors like Zydus and Alembic, along with Lupin's progress in addressing past FDA regulatory observations, will be key. Future product approvals and the overall impact on Lupin's diabetes segment revenue and profitability will also be closely monitored.